Si Qi Chen
About Si Qi Chen
Si Qi Chen is the Associate Director Excellence & Engagement - US Medical Lymphoma at Bristol Myers Squibb, with extensive experience in regulatory affairs, project management, and digital transformation within the pharmaceutical industry.
Title
Si Qi Chen currently holds the title of Associate Director Excellence & Engagement - US Medical Lymphoma at Bristol Myers Squibb.
Company
Si Qi Chen works at Bristol Myers Squibb in Summit, NJ, where they serve as Associate Director Excellence & Engagement - US Medical Lymphoma. They manage interactions and communications between field medical teams and the home office.
Education and Expertise
Si Qi Chen completed their Master of Business Administration (MBA) at INSEAD, specializing in Business Administration and Management. They hold a Master of Science (MS) in Cell and Molecular Biology Oncology from The Rockefeller University, and a Bachelor of Science (BS) in Molecular Biology and Economics from Massachusetts Institute of Technology (MIT). They have extensive expertise in managing regulatory affairs, commercial compliance projects, and digital transformation within the pharmaceutical industry.
Professional Background
Si Qi Chen has a dynamic career spanning over 15 years, involving roles at several esteemed organizations. Notably, they worked at NJOY in various capacities, including Sr. Director and Director of Program Management Regulatory Affairs. They also held positions at Luxoft providing services to Novartis as Project Manager in both US and Global Oncology. Additionally, they were involved in consulting roles at Nuvera Life Science Consulting, Polaris Management Partners, and Simon Kucher & Partners. Their early career includes roles at Mars & Company, Trinity Partners, and a summer internship at Philips.
Achievements in Regulatory Affairs
Si Qi Chen has contributed significantly to regulatory affairs and corporate strategy in their roles. At NJOY, they managed program management and regulatory affairs for nearly three years. They also played a key role in pricing and market access strategies at Luxoft/Novartis and demonstrated expertise in commercial compliance projects across various therapeutic areas like oncology and infectious diseases.